Captor Therapeutics (WAR:CTX) EV-to-EBIT : -4.03 (As of May. 12, 2024)

Captor Therapeutics EV-to-EBIT Chart

Captor Therapeutics Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial														-16.39	-14.88	-10.11	-6.39	-5.52

Competitive Comparison of Captor Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Captor Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Captor Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Captor Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Captor Therapeutics's EV-to-EBIT falls into.

Captor Therapeutics EV-to-EBIT Calculation

Captor Therapeutics's EV-to-EBIT for today is calculated as:

Captor Therapeutics's current Enterprise Value is zł283.01 Mil.
Captor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-70.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Captor Therapeutics  (WAR:CTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Captor Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Captor Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was zł388.00 Mil.
Captor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-70.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Captor Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Captor Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Captor Therapeutics (WAR:CTX) Business Description